ALX Oncology reports preliminary Q3 2023 cash position of $196.5M

ALX ONCOLOGY HOLDINGS INC

Preliminary cash, cash equivalents, and investments of $196.5M as of Sep 30, 2023, subject to quarter-end close.
Estimate is unaudited and may change upon completion of financial statement closing procedures.
No other Q3 financial results released; full report expected later.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALX ONCOLOGY HOLDINGS INC reported preliminary financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: preliminary results

Exact text from the filing

ALX Oncology Holdings Inc. (the “Company”), announced its preliminary estimate of cash, cash equivalents and short-term and long-term investments for the third quarter ended September 30, 2023. Based upon preliminary estimates and information available to the Company as of the date of this Form 8-K, it had approximately $196.5 million of cash, cash equivalents and short-term and long-term investments as of September 30, 2023.

View on SEC.gov

Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0001193125-23-250822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.